The Use of Anti-Müllerian Hormone in Predicting Menstrual Response after Weight Loss in Overweight Women with Polycystic Ovary Syndrome
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is associated with reproductive and metabolic abnormalities, specifically menstrual dysfunction and anovulation in conjunction with elevated pre-antral follicle number and arrested follicular maturation. Although anti-müllerian hormone (AMH), an inhibitor of follicle recruitment and maturation, is increased in women with PCOS, the usefulness of circulating AMH levels as a clinical predictor of menstrual response to weight loss in PCOS is not known. METHODS: Overweight women with PCOS (n = 26, age 32.9 +/- 5.8 yr, weight 98.9 +/- 20.8 kg, body mass index 36.1 +/- 7.0 kg/m(2), mean +/- sd) followed an 8-wk weight loss and 6-month weight maintenance program. RESULTS: Net reductions in weight (4.6 +/- 4.8 kg), waist circumference (6.0 +/- 5.3 cm), testosterone (0.3 +/- 0.6 nmol/liter), fasting insulin (3.7 +/- 7.6 mU/liter), and the homeostasis model assessment of insulin sensitivity (0.7 +/- 1.3) occurred for all subjects over the entire study duration. Of 26 subjects, 15 (57.7%) responded to the intervention with improvements in menstrual cyclicity (responders). Compared to nonresponders, responders had lower AMH levels at baseline (23.6 +/- 12.0 vs. 37.9 +/- 17.8 pmol/liter; P = 0.021). Only responders had reductions in fasting insulin (6.1 +/- 5.9 mU/liter; P = 0.001) and homeostasis model assessment (1.3 +/- 5.9; P = 0.002) with acute weight loss (wk 0-8). Baseline AMH was most strongly predicted by baseline ghrelin, free testosterone, and insulin (r(2) = 0.528; P = 0.002). CONCLUSIONS: Overweight women with PCOS who respond to weight loss with menstrual improvements have significantly reduced preweight loss AMH and demonstrate improvements in surrogate measures of insulin resistance with weight loss. Pretreatment AMH is a potential clinical predictor of menstrual improvements with weight loss in PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824 · cited 1×
“The free androgen index (FAI) (testosterone/ SHBG 100) and equilibrium binding equations for determination of free testosterone (27) were used as surrogate estimates of free testosterone.”
MethodProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Andrology: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients
Balen, A. H., Conway, G. S., Kaltsas, G., Techatraisak, K., Manning, P. J., West, C., & Jacobs, H. S. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a136243 · Cited by 1,060
Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1502 · Cited by 789 · cited 1×
“Weight loss is a key initial treatment strategy in obese women with PCOS, and improves insulin sensitivity, hyperandrogenism, metabolic risk factors, menstrual function and ovulation (4–6), fertility and reproductive outcomes (6), and reduces ovarian volume and follicle number (4).”
BackgroundSelf-citationAndrogens stimulate early stages of follicular growth in the primate ovary
Vendola, K. A., Zhou, J., Adesanya, O. O., Weil, S. J., & Bondy, C. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2081 · Cited by 712 · cited 1×
“In PCOS, anovulation and menstrual irregularity are characterized by excessive early follicular growth with significantly greater amounts of primary and pre-antral follicles (7), likely caused by elevated intraovarian androgens augmenting thecal and granulosa cell growth (8).”
BackgroundPigny, P., Merlen, E., Robert, Y., Cortet-Rudelli, C., Decanter, C., Jonard, S., & Dewailly, D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030727 · Cited by 709 · cited 10×
“atively correlates with FSH (19, 40, 41), estradiol (42, 43) and”
BackgroundResultInfluentialMoran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Self-citationDefinitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome
Hart, R., Hickey, M., & Franks, S. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2004.05.001 · Cited by 358
Norman, R. J., Masters, L., Milner, C. R., Wang, J. X., & Davies, M. J. (2001) · Human Reproduction · doi:10.1093/humrep/16.9.1995 · Cited by 341 · cited 1×
“This is preferable in conjunction with lifestyle management to optimize improvement of other metabolic risk factors commonly present in PCOS (2).”
BackgroundSelf-citation
Cited by
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)
La Marca, A., Sighinolfi, G., Radi, D., Argento, C., Baraldi, E., Artenisio, A. C., Stabile, G., & Volpe, A. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmp036 · Cited by 956
Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis
Escobar-Morreale, H. F., Luque-Ramírez, M., & González, F. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.11.036 · Cited by 517
Anti-Mullerian hormone (AMH): what do we still need to know?
La Marca, A., Broekmans, F. J., Volpe, A., Fauser, B. C., Macklon, N. S., & on behalf of the ESHRE Special Interest Group for Reproductive Endocrinology - AMH Round Table (2009) · Human Reproduction · doi:10.1093/humrep/dep210 · Cited by 327
The role of AMH in the pathophysiology of polycystic ovarian syndrome
Garg, D., & Tal, R. (2016) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2016.04.007 · Cited by 150
Nylander, M., Frøssing, S., Clausen, H. V., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.03.023 · Cited by 139
Palomba, S., Falbo, A., Giallauria, F., Russo, T., Rocca, M., Tolino, A., Zullo, F., & Orio, F. (2010) · Human Reproduction · doi:10.1093/humrep/deq254 · Cited by 111
“Several factors have been hypothesized to be involved in the clinical efficacy of the lifestyle interventions (Moran et al., 2007a,b; Thomson et al., 2009).”
BackgroundMoini, A., Arabipoor, A., Hemat, M., Ahmadi, J., Salman-Yazdi, R., & Zolfaghari, Z. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1499084 · Cited by 12
Metadata
- Authors
- Moran, L. J., Noakes, M., Clifton, P. M., & Norman, R. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 92
- Issue
- 10
- Pages
- 3796-3802
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1974186567
- Cited by
- 58
- References
- 15
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.